See more : Citizens Bancorp of Virginia, Inc. (CZBT) Income Statement Analysis – Financial Results
Complete financial analysis of Marksans Pharma Limited (MARKSANS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marksans Pharma Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Equippp Social Impact Technologies Limited (EQUIPPP.BO) Income Statement Analysis – Financial Results
- Nandan Denim Limited (NDL.BO) Income Statement Analysis – Financial Results
- PT Pulau Subur Tbk (PTPS.JK) Income Statement Analysis – Financial Results
- TAURON Polska Energia S.A. (TPE.WA) Income Statement Analysis – Financial Results
- D. Western Therapeutics Institute, Inc. (4576.T) Income Statement Analysis – Financial Results
Marksans Pharma Limited (MARKSANS.BO)
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.77B | 18.50B | 14.80B | 13.68B | 11.29B | 9.87B | 9.04B | 7.59B | 8.93B | 7.97B | 6.30B | 4.38B | 3.56B | 3.05B | 3.59B | 3.60B | 2.64B | 2.42B | 2.97B | 2.53B |
| Cost of Revenue | 10.94B | 9.21B | 7.17B | 6.19B | 5.91B | 5.17B | 5.48B | 4.68B | 5.22B | 4.45B | 3.68B | 2.53B | 2.13B | 2.03B | 2.94B | 2.87B | 2.00B | 1.97B | 2.29B | 1.89B |
| Gross Profit | 10.83B | 9.28B | 7.63B | 7.50B | 5.38B | 4.70B | 3.56B | 2.91B | 3.71B | 3.51B | 2.62B | 1.86B | 1.43B | 1.02B | 651.94M | 734.70M | 637.59M | 452.54M | 682.54M | 642.02M |
| Gross Profit Ratio | 49.75% | 50.19% | 51.57% | 54.79% | 47.64% | 47.59% | 39.36% | 38.30% | 41.54% | 44.09% | 41.60% | 42.32% | 40.11% | 33.42% | 18.14% | 20.40% | 24.16% | 18.70% | 22.95% | 25.39% |
| Research & Development | 199.32M | 148.97M | 297.89M | 127.49M | 83.15M | 57.13M | 52.66M | 45.31M | 76.81M | 171.98M | 0.00 | 45.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.18M | 50.04M | 46.73M |
| General & Administrative | 176.97M | 162.62M | 148.37M | 238.83M | 179.66M | 232.05M | 206.30M | 204.54M | 214.54M | 66.85M | 74.12M | 57.31M | 0.00 | 199.75M | 407.47M | 442.36M | 315.78M | 241.32M | 190.45M | 167.48M |
| Selling & Marketing | 1.27B | 1.03B | 1.19B | 1.10B | 792.60M | 666.31M | 475.90M | 260.76M | 99.13M | 116.82M | 267.64M | 223.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.06B | 1.19B | 1.34B | 1.33B | 972.25M | 898.35M | 682.20M | 465.31M | 313.67M | 183.66M | 1.09B | 915.21M | 0.00 | 199.75M | 407.47M | 442.36M | 315.78M | 241.32M | 190.45M | 167.48M |
| Other Expenses | 0.00 | 74.93M | 95.62M | 38.73M | 1.50M | 903.63K | 1.99M | 37.71M | -8.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.29B | 6.15B | 5.47B | 4.31B | 3.72B | 3.61B | 3.04B | 2.88B | 2.67B | 1.91B | 1.60B | 1.31B | 2.66B | 1.95B | 546.57M | 521.31M | 351.45M | 272.01M | 273.85M | 267.34M |
| Cost & Expenses | 13.98B | 15.37B | 12.63B | 10.50B | 9.64B | 8.78B | 8.52B | 7.56B | 7.89B | 6.37B | 5.28B | 3.84B | 4.79B | 3.98B | 3.49B | 3.39B | 2.35B | 2.24B | 2.57B | 2.15B |
| Interest Income | 337.87M | 120.37M | 59.73M | 11.59M | 1.00M | 885.46K | 1.06M | 2.44M | 24.79M | 32.76M | 7.20M | 9.97M | 20.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.03M | 57.46M | 53.90M | 34.67M | 49.70M | 59.25M | 64.94M | 39.61M | 62.94M | 86.98M | 103.96M | 145.96M | 535.75M | 436.67M | 192.31M | 213.59M | 118.55M | 115.02M | 50.45M | 59.29M |
| Depreciation & Amortization | 742.70M | 518.53M | 447.76M | 361.51M | 266.62M | 228.04M | 268.38M | 300.93M | 281.27M | 161.34M | 156.91M | 156.50M | 237.00M | 1.92M | 154.74M | 153.55M | 92.85M | 73.27M | 80.48M | 69.50M |
| EBITDA | 5.09B | 3.99B | 3.01B | 3.46B | 1.93B | 1.37B | 868.57M | 329.19M | 1.45B | 1.76B | 1.14B | 706.50M | -997.41M | -913.68M | 254.79M | 297.15M | 416.53M | 281.57M | 444.99M | 379.46M |
| EBITDA Ratio | 23.38% | 22.74% | 19.90% | 25.90% | 16.72% | 13.45% | 9.20% | 6.44% | 15.81% | 22.69% | 17.86% | 16.03% | -28.05% | -30.00% | 7.13% | 8.30% | 15.79% | 11.64% | 15.32% | 15.24% |
| Operating Income | 7.79B | 3.00B | 2.06B | 2.99B | 1.62B | 979.09M | 443.40M | 155.29M | 1.07B | 1.56B | 864.11M | 435.47M | -1.75B | -915.60M | 101.45M | 145.51M | 323.93M | 208.31M | 314.06M | 250.68M |
| Operating Income Ratio | 35.78% | 16.21% | 13.94% | 21.83% | 14.33% | 9.92% | 4.90% | 2.05% | 11.96% | 19.57% | 13.72% | 9.93% | -49.22% | -30.06% | 2.82% | 4.04% | 12.27% | 8.61% | 10.56% | 9.91% |
| Total Other Income/Expenses | -3.56B | -3.06B | -2.69B | -2.46B | -46.11M | -50.28M | -18.01M | -1.24B | -1.31B | -947.42M | -373.33M | 0.00 | 0.00 | -419.16M | -197.64M | -215.50M | -81.02M | -87.24M | -1.00 | -101.73M |
| Income Before Tax | 4.24B | 3.38B | 2.48B | 3.02B | 1.57B | 1.04B | 497.98M | 148.97M | 1.07B | 1.56B | 864.11M | 435.47M | -1.75B | -1.35B | -92.27M | -69.99M | 205.13M | 93.29M | 314.06M | 250.68M |
| Income Before Tax Ratio | 19.45% | 18.26% | 16.72% | 22.08% | 13.92% | 10.56% | 5.51% | 1.96% | 11.96% | 19.57% | 13.72% | 9.93% | -49.22% | -44.40% | -2.57% | -1.94% | 7.77% | 3.85% | 10.56% | 9.91% |
| Income Tax Expense | 1.09B | 723.32M | 606.97M | 636.26M | 364.19M | 238.69M | 139.97M | 35.63M | 241.08M | 439.21M | 127.87M | -52.79M | 10.76M | 802.17M | 3.95M | 9.56M | 47.94M | 26.36M | 85.15M | 45.09M |
| Net Income | 3.14B | 2.66B | 1.85B | 2.39B | 1.21B | 804.37M | 358.01M | 88.39M | 785.12M | 1.09B | 719.08M | 458.84M | -1.79B | -13.87M | -100.43M | -83.55M | 157.19M | 66.93M | 228.91M | 205.59M |
| Net Income Ratio | 14.41% | 14.40% | 12.47% | 17.43% | 10.69% | 8.15% | 3.96% | 1.16% | 8.79% | 13.73% | 11.41% | 10.47% | -50.30% | -0.46% | -2.79% | -2.32% | 5.96% | 2.77% | 7.70% | 8.13% |
| EPS | 6.92 | 6.41 | 4.51 | 5.76 | 2.86 | 1.97 | 0.87 | 0.22 | 1.92 | 2.67 | 1.87 | 1.19 | -4.86 | -0.04 | -0.27 | -0.23 | 0.43 | 0.19 | 0.64 | 0.00 |
| EPS Diluted | 6.92 | 6.41 | 4.51 | 5.76 | 2.86 | 1.97 | 0.87 | 0.22 | 1.92 | 2.67 | 1.87 | 1.19 | -4.64 | -0.04 | -0.27 | -0.23 | 0.43 | 0.19 | 0.64 | 0.00 |
| Weighted Avg Shares Out | 453.32M | 415.40M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 385.31M | 385.31M | 367.81M | 367.78M | 367.81M | 363.61M | 367.10M | 351.62M | 359.41M | 0.00 |
| Weighted Avg Shares Out (Dil) | 453.16M | 415.40M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 409.31M | 385.31M | 385.31M | 385.31M | 367.78M | 367.81M | 363.61M | 367.10M | 351.62M | 359.41M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports